Characteristics and outcomes of hospitalized patients with cardiovascular complications of COVID-19
Authors:
- Farzad JalaliFJFarzad Jalali
- Farbod HatamiFHFarbod Hatami
- Mehrdad SaraviMSMehrdad Saravi
- Iraj JafaripourIJIraj Jafaripour
- Mohammad Taghi HedayatiMHMohammad Taghi Hedayati
- Kamyar AminKAKamyar Amin
- Roghayeh PourkiaRPRoghayeh Pourkia
- Mostafa JavanianMJMostafa Javanian
- Soheil EbrahimpourSoheil Ebrahimpour
- Niloufar ValizadehNVNiloufar Valizadeh
- Saeede Khosravi BizhaemSBSaeede Khosravi Bizhaem
Open Access
- 6 December 2021
- journal article
- research article
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 13 (4) , 355-363
Abstract
Introduction: To address cardiovascular (CV) complications and their relationship to clinical outcomes in hospitalized patients with COVID-19. Methods: A total of 196 hospitalized patients with COVID-19 were enrolled in this retrospective single-center cohort study from September 10, 2020, to December 10, 2020, with a median age of 65 years (IQR, 52-77). Follow-up continued for 3 months after hospital discharge. Results: CV complication was observed in 54 (27.6%) patients, with arrhythmia being the most prevalent (14.8%) followed by myocarditis, acute coronary syndromes, ST-elevation myocardial infarction, cerebrovascular accident, and deep vein thrombosis in 15 (7.7%), 12 (6.1%), 10(5.1%), 8 (4.1%), and 4 (2%) patients, respectively. The proportion of patients with elevated high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction was greater in the CV complication group. Severe forms of COVID-19 comprised nearly two-thirds (64.3%) of our study population and constituted a significantly higher share of the CV complication group members (75.9%vs 59.9%; P=0.036). Intensive care unit admission (64.8% vs 44.4%; P=0.011) and stay (5.5days vs 0 day; P=0.032) were notably higher in patients with CV complications. Among 196patients, 50 died during hospitalization and 10 died after discharge, yielding all-cause mortality of 30.8%. However, there were no between-group differences concerning mortality. Age, heart failure, cancer/autoimmune disease, disease severity, interferon beta-1a, and arrhythmia were the independent predictors of all-cause mortality during and after hospitalization. Conclusion: CV complications occurred widely among COVID-19 patients. Moreover,arrhythmia, as the most common complication, was associated with increased mortality.Keywords
This publication has 27 references indexed in Scilit:
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, ChinaJAMA Cardiology, 2020
- Pathological findings of COVID-19 associated with acute respiratory distress syndromeThe Lancet Respiratory Medicine, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress SyndromeJAMA, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Therapeutic effect of subcutaneous injection of low dose recombinant human granulocyte-macrophage colony-stimulating factor on pulmonary alveolar proteinosisRespiratory Research, 2020
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failurePolish Heart Journal, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirusJournal of Infection, 2013
- MyocarditisThe Lancet, 2012